Payer Policy

UnitedHealthcare Prior Authorization Guide 2026: Policies, Timelines & Appeals

UnitedHealthcare prior authorization requirements, OptumRx formulary policies, clinical coverage criteria, peer-to-peer contact numbers, and appeal strategies for 2026.

RxCheckUp Clinical Team · 2026-05-11 · 13 min read

UnitedHealthcare Prior Authorization Overview

UnitedHealthcare (UHC) is the largest commercial health insurer in the United States, covering more than 49 million members across employer-sponsored, Medicare Advantage, Medicaid managed care, and individual market plans. Its pharmacy benefit management arm, OptumRx, administers drug coverage for the majority of UHC-insured members as well as many self-insured employer clients. Understanding how UHC structures its prior authorization program — including which policies govern each decision, how long reviews take, and where the clinical leverage points are — is essential for any practice managing specialty prescriptions.

UHC publishes its clinical coverage determinations under the UnitedHealthcare Coverage Determination Guidelines (CDGs) for medical benefits and through OptumRx clinical criteria for pharmacy benefits. These are two distinct policy frameworks that govern benefits delivered through different channels: the medical benefit (Part B equivalent for commercial; J-code billing for infused or injected drugs administered in an office or infusion center) and the pharmacy benefit (typically retail, specialty pharmacy, or home infusion). The correct policy depends on where and how the drug is administered, and submitting a prior auth against the wrong policy is one of the most common causes of preventable delays.

How UHC Prior Authorization Works: The Two Tracks

Medical benefit prior authorization at UHC covers drugs administered by a healthcare provider in a clinical setting — infused biologics, oncology infusions, injectable medications administered in-office, and similar. These are routed through UHC's clinical services teams using J-codes and NDCs. PA requests for medical benefit drugs are submitted via Availity or UHC's Provider Portal, and decisions are made against the applicable CDG.

Pharmacy benefit prior authorization covers drugs dispensed through retail or specialty pharmacy. OptumRx manages this channel. PA requests are submitted by the prescriber or pharmacy through OptumRx's pharmacy portal or automated phone IVR. The clinical criteria document governing the decision is the OptumRx Prior Authorization Criteria, which is published online and updated quarterly.

When a drug spans both channels — for example, a biologic available both as a self-injected specialty product (pharmacy benefit) and as an IV infusion (medical benefit) — UHC may have different prior auth criteria for each route. Prescribers should confirm which channel the patient's plan covers the specific drug under before submitting to avoid a mismatch denial.

✓ Medical benefit PA: submit via Availity, UHC Provider Portal, or fax to the appropriate clinical services number on the patient's ID card
✓ Pharmacy benefit PA: submit via OptumRx Provider Portal or through the dispensing specialty pharmacy
✓ ePA-capable prescriptions can be submitted directly through the EHR via Surescripts RTBT (Real-Time Benefit and Treatment) for OptumRx
✓ Urgent PA requests: UHC processes expedited requests within 72 hours; routine requests within 3 business days for most commercial plans
✓ Always confirm the drug's benefit channel (medical vs pharmacy) before submitting — wrong channel = automatic denial and restart

UnitedHealthcare Coverage Determination Guidelines (CDGs)

CDGs are UHC's clinical coverage policies for the medical benefit. Each CDG covers one drug or drug class and specifies the FDA-approved and off-label indications UHC will cover, the step therapy and prior-treatment requirements, the required documentation (labs, imaging, specialist notes), and the duration of approval.

CDGs are publicly available at uhcprovider.com under "Policies and Protocols." The search function allows lookup by drug name, policy number, or indication. UHC revises CDGs periodically — typically quarterly — so policies in effect at the time of a denial may differ from the version published when you originally checked. Always download the CDG that was current on the date of the PA decision when preparing an appeal.

When a CDG denial cites a specific criterion number, the appeal must address that criterion directly. A CDG typically organizes criteria into numbered or lettered conditions (e.g., "Criterion A: diagnosis confirmation," "Criterion B: prior therapy"). If the denial letter says the request "does not meet Criterion B," an appeal that addresses Criterion A and the clinical rationale for the drug without addressing Criterion B will be upheld on the same grounds.

OptumRx Specialty Drug Prior Authorization Criteria

For pharmacy-benefit drugs, OptumRx publishes its prior authorization criteria online. Key elements of the OptumRx PA criteria framework include: approved indications with ICD-10 codes, required prior therapy steps, required laboratory values (e.g., DLQI score for dermatologic drugs, HbA1c for diabetes agents), quantity and duration limits, and site-of-care requirements for drugs that can be administered in multiple settings.

OptumRx has broadly adopted specialty pharmacy channel management, meaning most specialty drugs must be dispensed through an OptumRx-affiliated specialty pharmacy (Optum Specialty Pharmacy, BioPlus, Diplomat) rather than the patient's local retail pharmacy. PA approvals for specialty drugs often come with a mandatory specialty pharmacy designation. Practices should confirm the dispensing channel at the time of PA submission to avoid a fill rejection after approval.

OptumRx also operates a site-of-care program (Optum Infusion Pharmacy) for drugs that can transition from hospital/clinic infusion to home infusion. Expect PA criteria for infused biologics to include a site-of-care evaluation — UHC/OptumRx may approve the drug but require home infusion after the first 1-3 clinical site doses, particularly for stable patients on maintenance therapy.

Step Therapy and Prior Treatment Requirements

UHC's step therapy requirements are among the most clearly documented of any major commercial payer. For most biologic drug classes, UHC requires documented failure of at least one conventional therapy before approving the biologic. The specific prior-treatment requirements vary by drug class:

✓ TNF inhibitors (adalimumab, etanercept, infliximab): typically require documented failure of at least one conventional DMARD (methotrexate, sulfasalazine, leflunomide) for RA indications; CDG specifies minimum trial duration (usually 3 months)
✓ IL-17/IL-23 inhibitors (secukinumab, ixekizumab, guselkumab, risankizumab): for PsA, failure of one prior DMARD or TNF inhibitor commonly required
✓ GLP-1s (semaglutide, tirzepatide): OptumRx criteria require documented BMI threshold (≥30 for obesity indication, ≥27 with comorbidity), failed lifestyle modification attempt, and absence of contraindications
✓ Multiple sclerosis agents (natalizumab, ocrelizumab, ofatumumab): typically no step therapy for relapsing forms; criteria focus on diagnosis confirmation by neurologist and MRI documentation
✓ Oncology: most oncology drugs bypass step therapy under NCCN guidelines; UHC generally follows NCCN Categories 1 and 2A for oncology PA decisions
✓ Step therapy exemptions: UHC complies with state step therapy exemption laws (e.g., AR, CT, FL, IL, TX); for Medicare Advantage, CMS step therapy rules apply

Required Documentation for UHC PA Submissions

UHC and OptumRx denials most often cite missing or insufficient documentation rather than outright clinical disagreement. The most commonly required documents that practices omit:

✓ Diagnosis confirmation with ICD-10 code at the maximum specificity level (e.g., M05.79, not M05.7)
✓ Prior therapy documentation: drug name, dose, start and stop dates, reason for discontinuation (side effect, inadequate response, contraindication)
✓ Relevant lab values: HbA1c for T2D drugs, ESR/CRP/DAS28 for RA, PASI/DLQI for plaque psoriasis, FEV1 for respiratory biologics
✓ Specialist involvement: many CDGs require the PA request to originate from or be co-signed by the appropriate specialist (rheumatologist for RA biologics, pulmonologist for severe asthma biologics)
✓ Diagnosis-specific imaging or objective measures: MRI for MS, echocardiogram for certain cardiac drugs, sleep study for OSA
✓ Weight and BMI for GLP-1 and obesity-related requests

UHC Prior Authorization Appeal Process

UHC's internal appeal process for commercial plans follows a two-level structure: first-level internal appeal, then second-level (final) internal appeal before external review becomes available. The timeline for each level is governed by whether the plan is fully insured (state law deadlines apply) or self-insured ERISA (federal ERISA timelines apply).

For commercial fully-insured plans, UHC must respond to first-level appeals within 30 days for pre-service decisions (or 72 hours for urgent). For ERISA plans, the appeal must be decided within 60 days for pre-service and 45 days for post-service. Missing these deadlines is itself a violation and can be cited in the external review filing.

Peer-to-peer (P2P) review is available for UHC medical benefit denials and many OptumRx pharmacy benefit denials. The P2P line is typically printed on the denial letter, or accessible through the UHC Provider Portal. Request a P2P within 24 hours of receiving a denial for best access to the original reviewing clinician. At UHC, P2P calls are usually scheduled within 1-3 business days, and the reviewing physician is typically a specialty-matched clinician (e.g., a rheumatologist reviews RA biologic cases). Peer-to-peer overturns approximately 40-60% of UHC specialty drug denials when the prescriber is well-prepared.

Writing a Strong UHC Appeal Letter

An effective UHC appeal letter follows the CDG or OptumRx criteria structure directly. Reviewers are scored on their compliance with written criteria — if you address criteria by number and show compliance point-by-point, the reviewer's ability to uphold the denial shrinks substantially.

✓ Open with the citation: "This appeal responds to the denial of [drug] dated [date] under CDG [policy number], Criterion [X]."
✓ Address the specific denial criterion and explain why the clinical documentation meets it
✓ Attach the exact documentation the CDG requires: lab values, prior therapy dates, specialist notes, imaging
✓ Cite the most recent NCCN guideline (for oncology), ACR (rheumatology), ADA (diabetes), or relevant specialty society guideline with the specific recommendation number
✓ If the denial is based on step therapy, document why the required prior therapy is contraindicated or was tried and failed — with dates
✓ Request expedited review if the patient's condition is urgent or if delay would cause significant harm
✓ Include peer-reviewed evidence: 1-2 RCTs and the product's FDA label section most relevant to the patient's diagnosis

UHC Medicare Advantage Prior Authorization

UHC is the largest Medicare Advantage insurer nationally. UHC MA plans (UHC AARP, UHC Community Plan Medicare, and others) follow CMS requirements, which set mandatory timelines and appeal rights that differ from commercial plans.

UHC MA standard PA decisions must be issued within 14 calendar days for pre-service requests. Expedited decisions must be issued within 72 hours. These CMS-mandated timelines are non-negotiable and non-waivable; if UHC misses them, the denial is vacated by operation of law, and the service is deemed approved.

UHC MA appeals go through a four-level process: Level 1 (Organization Determination), Level 2 (Reconsideration — must be conducted by an independent review entity under CMS contract), Level 3 (ALJ hearing, available if the amount in controversy meets the threshold), Level 4 (Medicare Appeals Council). For specialty drugs, Level 2 external review — conducted by Maximus Federal Services or other CMS-contracted IRE — overturns UHC MA denials at a nationally significant rate. Prescribers should not stop at Level 1 if the clinical case is strong.

Contact Information and Submission Channels

UHC prior authorization submission channels vary by plan type. Always confirm the correct number from the member's ID card or the UHC Provider Portal.

✓ UHC commercial medical benefit PA: submit via uhcprovider.com or Availity; fax numbers on Provider Portal by plan type
✓ OptumRx specialty pharmacy PA: OptumRx Provider Portal or call 1-800-711-4555
✓ UHC Medicare Advantage PA: use uhcprovider.com/cs/satellite/uhcprovider for MA-specific workflows
✓ Peer-to-peer: request via the denial letter's listed number or through UHC Provider Portal case management
✓ Expedited PA phone line: listed on member ID card (Commercial: often listed as "Precertification"); ask for "expedited" at the IVR prompt
✓ Electronic prior authorization: supported via Surescripts RTBT and most major EHR integrations through Availity; ePA reduces average decision time significantly vs fax